{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T14:32:17Z","timestamp":1793716337863,"version":"4.6.1"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T00:00:00Z","timestamp":1780099200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"vor","delay-in-days":66,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virol J"],"DOI":"10.1186\/s12985-026-03178-2","type":"journal-article","created":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T05:46:48Z","timestamp":1780292808000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Post-marketing safety profile of bictegravir\/emtricitabine\/tenofovir alafenamide: a FAERS pharmacovigilance study with EudraVigilance validation and mechanistic investigation of pancreatitis"],"prefix":"10.1186","volume":"23","author":[{"given":"Yuxin","family":"Xie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yawen","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinghua","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoqing","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihuai","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiwei","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengyu","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,30]]},"reference":[{"key":"3178_CR1","doi-asserted-by":"crossref","unstructured":"GBD 2021 Causes of Death Collaborators. Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2024;403(10440):2100-2132.","DOI":"10.1016\/S0140-6736(24)00367-2"},{"key":"3178_CR2","doi-asserted-by":"publisher","first-page":"115862","DOI":"10.1016\/j.bcp.2023.115862","volume":"217","author":"E De Clercq","year":"2023","unstructured":"De Clercq E, Zhang Z, Huang J, Zhang M, Li G. Biktarvy for the treatment of HIV infection: Progress and prospects. Biochem Pharmacol. 2023;217:115862.","journal-title":"Biochem Pharmacol"},{"issue":"6","key":"3178_CR3","doi-asserted-by":"publisher","first-page":"e389","DOI":"10.1016\/S2352-3018(20)30099-0","volume":"7","author":"C Orkin","year":"2020","unstructured":"Orkin C, Dejesus E, Sax PE, Arribas JR, Gupta SK, Martorell C, Stephens JL, Stellbrink HJ, Wohl D, Maggiolo F, Thompson MA, Podzamczer D, Hagins D, Flamm JA, Brinson C, Clarke A, Huang H, Acosta R, Brainard DM, Collins SE, Martin H. Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials. Lancet HIV. 2020;7(6):e389\u2013400.","journal-title":"Lancet HIV"},{"issue":"10107","key":"3178_CR4","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1016\/S0140-6736(17)32340-1","volume":"390","author":"PE Sax","year":"2017","unstructured":"Sax PE, Pozniak A, Montes ML, Koenig E, Dejesus E, Stellbrink HJ, Antinori A, Workowski K, Slim J, Reynes J, Garner W, Custodio J, White K, Sengupta D, Cheng A, Quirk E. Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial. Lancet. 2017;390(10107):2073\u201382.","journal-title":"Lancet"},{"issue":"10107","key":"3178_CR5","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1016\/S0140-6736(17)32299-7","volume":"390","author":"J Gallant","year":"2017","unstructured":"Gallant J, Lazzarin A, Mills A, Orkin C, Podzamczer D, Tebas P, Girard PM, Brar I, Daar ES, Wohl D, Rockstroh J, Wei X, Custodio J, White K, Martin H, Cheng A, Quirk E. Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial. Lancet. 2017;390(10107):2063\u201372.","journal-title":"Lancet"},{"key":"3178_CR6","doi-asserted-by":"publisher","first-page":"101991","DOI":"10.1016\/j.eclinm.2023.101991","volume":"59","author":"PE Sax","year":"2023","unstructured":"Sax PE, Arribas JR, Orkin C, Lazzarin A, Pozniak A, Dejesus E, Maggiolo F, Stellbrink HJ, Yazdanpanah Y, Acosta R, Huang H, Hindman JT, Martin H, Baeten JM, Wohl D. Bictegravir\/emtricitabine\/tenofovir alafenamide as initial treatment for HIV-1: five-year follow-up from two randomized trials. EClinicalMedicine. 2023;59:101991.","journal-title":"EClinicalMedicine"},{"key":"3178_CR7","doi-asserted-by":"publisher","unstructured":"Esen BH, Bektas SN, Topcu U, et al. Immune-related adverse events in older adults receiving immune checkpoint inhibitors: a comprehensive analysis of the Food and Drug Administration Adverse Event Reporting System. Age Ageing. 2025;54(1):afaf008. https:\/\/doi.org\/10.1093\/ageing\/afaf008","DOI":"10.1093\/ageing\/afaf008"},{"key":"3178_CR8","doi-asserted-by":"publisher","first-page":"1442765","DOI":"10.3389\/fphar.2024.1442765","volume":"15","author":"D Zhang","year":"2024","unstructured":"Zhang D, Cai Y, Sun Y, Zeng P, Wang W, Wang W, Jiang X, Lian Y. A real-world pharmacovigilance study of Sorafenib based on the FDA Adverse Event Reporting System. Front Pharmacol. 2024;15:1442765.","journal-title":"Front Pharmacol"},{"key":"3178_CR9","doi-asserted-by":"publisher","first-page":"1765071","DOI":"10.3389\/fphar.2026.1765071","volume":"17","author":"Z Gong","year":"2026","unstructured":"Gong Z, He J, Feng Q, Liu D, Liu S. Drug-induced male infertility: a real-world study using FAERS and EudraVigilance databases. Front Pharmacol. 2026;17:1765071.","journal-title":"Front Pharmacol"},{"key":"3178_CR10","doi-asserted-by":"publisher","first-page":"1509310","DOI":"10.3389\/fphar.2024.1509310","volume":"15","author":"P Cao","year":"2024","unstructured":"Cao P, Wang Q, Wang Y, Qiao Q, Yan L. Safety assessment of tolvaptan: real-world adverse event analysis using the FAERS database. Front Pharmacol. 2024;15:1509310.","journal-title":"Front Pharmacol"},{"key":"3178_CR11","doi-asserted-by":"publisher","first-page":"1485190","DOI":"10.3389\/fphar.2024.1485190","volume":"15","author":"Q Liu","year":"2024","unstructured":"Liu Q, Cui Z, Deng C, Yang C, Shi T. A real-world pharmacovigilance analysis of adverse events associated with irbesartan using the FAERS and JADER databases. Front Pharmacol. 2024;15:1485190.","journal-title":"Front Pharmacol"},{"issue":"1","key":"3178_CR12","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s13195-024-01669-4","volume":"17","author":"X Xing","year":"2025","unstructured":"Xing X, Zhang X, Wang K, Wang Z, Feng Y, Li X, Hua Y, Zhang L, Dong X. Post-marketing safety concerns with lecanemab: a pharmacovigilance study based on the FDA Adverse Event Reporting System database. Alzheimers Res Ther. 2025;17(1):15.","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"3178_CR13","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s40360-025-00861-y","volume":"26","author":"H Hu","year":"2025","unstructured":"Hu H, Liu M, Fu Z, Li S, Wang K, Huang Z. The real-world safety profile of empagliflozin: a disproportionality analysis based on the FDA Adverse Event Reporting System (FAERS) database. BMC Pharmacol Toxicol. 2025;26(1):28.","journal-title":"BMC Pharmacol Toxicol"},{"issue":"5","key":"3178_CR14","doi-asserted-by":"publisher","first-page":"600","DOI":"10.23736\/S2724-6051.23.05304-1","volume":"75","author":"G Tema","year":"2023","unstructured":"Tema G, Lombardo R, Cicione A, Nacchia A, Gravina C, Franco A, Fiasconaro D, Sarcinelli L, Ghezzo N, Pastore A, Al Salhi Y, Fuschi A, Martoccia A, Tubaro A, C D E N. Adverse events related to darolutamide treatment: analysis of real life data from EudraVigilance and the Food and Drug Administration database entries. Minerva Urol Nephrol. 2023;75(5):600\u20136.","journal-title":"Minerva Urol Nephrol"},{"issue":"1","key":"3178_CR15","doi-asserted-by":"publisher","first-page":"31339","DOI":"10.1038\/s41598-025-16384-9","volume":"15","author":"F Yang","year":"2025","unstructured":"Yang F, Xu L, Lang X, Feng X. A real-world safety signal detection study of ondansetron based on FAERS reports from 2014 to 2024. Sci Rep. 2025;15(1):31339.","journal-title":"Sci Rep"},{"issue":"8","key":"3178_CR16","doi-asserted-by":"publisher","first-page":"591","DOI":"10.2165\/00002018-200427080-00010","volume":"27","author":"EG Brown","year":"2004","unstructured":"Brown EG. Using MedDRA: implications for risk management. Drug Saf. 2004;27(8):591\u2013602.","journal-title":"Drug Saf"},{"issue":"1","key":"3178_CR17","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/pds.668","volume":"11","author":"EP Van Puijenbroek","year":"2002","unstructured":"Van Puijenbroek EP, Bate A, Leufkens HG, Lindquist M, Orre R, Egberts AC. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf. 2002;11(1):3\u201310.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"3178_CR18","doi-asserted-by":"publisher","first-page":"123","DOI":"10.2174\/1574886318666230228142856","volume":"19","author":"F Javed","year":"2024","unstructured":"Javed F, Kumar A. Identification of Signal of Clindamycin Associated Renal Failure Acute: A Disproportionality Analysis. Curr Drug Saf. 2024;19(1):123\u20138.","journal-title":"Curr Drug Saf"},{"issue":"8","key":"3178_CR19","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1007\/s13300-024-01594-7","volume":"15","author":"S Xiong","year":"2024","unstructured":"Xiong S, Gou R, Liang X, Wu H, Qin S, Li B, Luo C, Chen J. Adverse Events of Oral GLP-1 Receptor Agonist (Semaglutide Tablets): A Real-World Study Based on FAERS from 2019 to 2023. Diabetes Ther. 2024;15(8):1717\u201333.","journal-title":"Diabetes Ther"},{"issue":"8","key":"3178_CR20","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/S0006-3223(98)00043-2","volume":"44","author":"F Curtin","year":"1998","unstructured":"Curtin F, Schulz P. Multiple correlations and Bonferroni\u2019s correction. Biol Psychiatry. 1998;44(8):775\u20137.","journal-title":"Biol Psychiatry"},{"issue":"1","key":"3178_CR21","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/jcpt.13024","volume":"45","author":"S Kinoshita","year":"2020","unstructured":"Kinoshita S, Hosomi K, Yokoyama S, Takada M. Time-to-onset analysis of amiodarone-associated thyroid dysfunction. J Clin Pharm Ther. 2020;45(1):65\u201371.","journal-title":"J Clin Pharm Ther"},{"issue":"9","key":"3178_CR22","doi-asserted-by":"publisher","first-page":"2705","DOI":"10.1016\/j.ekir.2024.07.006","volume":"9","author":"J Wang","year":"2024","unstructured":"Wang J, Zhang Z, Liu X, Shi S, Lv J, Zhang Y, Zhang H. Exploring Novel Adverse Events of Nefecon. Kidney Int Rep. 2024;9(9):2705\u201317.","journal-title":"Kidney Int Rep"},{"key":"3178_CR23","doi-asserted-by":"publisher","first-page":"996179","DOI":"10.3389\/fpubh.2022.996179","volume":"10","author":"Y Shu","year":"2022","unstructured":"Shu Y, He X, Wu P, Liu Y, Ding Y, Zhang Q. Gastrointestinal adverse events associated with semaglutide: A pharmacovigilance study based on FDA adverse event reporting system. Front Public Health. 2022b;10:996179.","journal-title":"Front Public Health"},{"issue":"W1","key":"3178_CR24","doi-asserted-by":"publisher","first-page":"W159","DOI":"10.1093\/nar\/gkac394","volume":"50","author":"Y Liu","year":"2022","unstructured":"Liu Y, Yang X, Gan J, Chen S, Xiao ZX, Cao Y. CB-Dock2: improved protein-ligand blind docking by integrating cavity detection, docking and homologous template fitting. Nucleic Acids Res. 2022;50(W1):W159\u201364.","journal-title":"Nucleic Acids Res"},{"issue":"5","key":"3178_CR25","doi-asserted-by":"publisher","first-page":"e13707","DOI":"10.1111\/jfbc.13707","volume":"45","author":"WJ Ni","year":"2021","unstructured":"Ni WJ, Chen XX, Wei SY, Lan LL, Qiu RJ, Ling YP, Zhou DS, Wu ZM, Cao ZH, Yu CP, Zeng Y. Study on the mechanism of active components of Liupao tea on 3CL(pro) based on HPLC-DAD fingerprint and molecular docking technique. J Food Biochem. 2021;45(5):e13707.","journal-title":"J Food Biochem"},{"issue":"7","key":"3178_CR26","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1097\/QAD.0000000000003865","volume":"38","author":"C Orkin","year":"2024","unstructured":"Orkin C, Antinori A, Rockstroh JK, Moreno-Guill\u00e9n S, Martorell CT, Molina JM, Lazzarin A, Maggiolo F, Yazdanpanah Y, Andreatta K, Huang H, Hindman JT, Martin H, Pozniak A. Switch to bictegravir\/emtricitabine\/tenofovir alafenamide from dolutegravir-based therapy. Aids. 2024;38(7):983\u201391.","journal-title":"Aids"},{"issue":"10","key":"3178_CR27","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1080\/14787210.2023.2279719","volume":"22","author":"L Gan","year":"2024","unstructured":"Gan L, Xie X, Fu Y, Yang X, Ma S, Kong L, Song C, Song Y, Ren T, Long H. Comparison of dolutegravir+Lamivudine and bictegravir\/emtricitabine\/tenofovir alafenamide in antiretroviral therapy-na\u00efve patients infected with HIV: preliminary results from clinical practice. Expert Rev Anti Infect Ther. 2024;22(10):877\u201384.","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"5","key":"3178_CR28","doi-asserted-by":"publisher","first-page":"e321","DOI":"10.1016\/S2352-3018(23)00328-4","volume":"11","author":"DM Byonanebye","year":"2024","unstructured":"Byonanebye DM, Polizzotto MN, Maltez F, Rauch A, Grabmeier-Pfistershammer K, Wit F, De Wit S, Castagna A, D\u2019arminio Monforte A, Mussini C, Wasmuth JC, Fontas E, Abela I, Sarcletti M, Bansi-Matharu L, Jaschinski N, Peters L, Hosein SR, Vannappagari V, Cohen C, Bissio E, Mocroft A, Law M, Ryom L, Petoumenos K. Associations between change in BMI and the risk of hypertension and dyslipidaemia in people receiving integrase strand-transfer inhibitors, tenofovir alafenamide, or both compared with other contemporary antiretroviral regimens: a multicentre, prospective observational study from the RESPOND consortium cohorts. Lancet HIV. 2024;11(5):e321\u201332.","journal-title":"Lancet HIV"},{"key":"3178_CR29","doi-asserted-by":"publisher","first-page":"106020","DOI":"10.1016\/j.antiviral.2024.106020","volume":"231","author":"P Garc\u00eda-Mart\u00ednez","year":"2024","unstructured":"Garc\u00eda-Mart\u00ednez P, Gisbert-Ferr\u00e1ndiz L, \u00c1lvarez \u00c1, Esplugues JV, Blas-Garc\u00eda A. Bictegravir alters glucose tolerance in vivo and causes hepatic mitochondrial dysfunction. Antiviral Res. 2024;231:106020.","journal-title":"Antiviral Res"},{"issue":"1","key":"3178_CR30","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1097\/COH.0000000000000833","volume":"19","author":"J Capeau","year":"2024","unstructured":"Capeau J, Lagathu C, B\u00e9r\u00e9ziat V. Recent data on the role of antiretroviral therapy in weight gain and obesity in persons living with HIV. Curr Opin HIV AIDS. 2024;19(1):14\u201320.","journal-title":"Curr Opin HIV AIDS"},{"issue":"9","key":"3178_CR31","doi-asserted-by":"publisher","first-page":"ofac451","DOI":"10.1093\/ofid\/ofac451","volume":"9","author":"M Iannetta","year":"2022","unstructured":"Iannetta M, Crea AMA, Di Lorenzo A, Campogiani L, Teti E, Malagnino V, Compagno M, Coppola L, Piermatteo L, Palmieri G, Cimino C, Salpini R, Zingaropoli MA, Ciardi MR, Mastroianni CM, Parisi SG, Svicher V, Andreoni M, Sarmati L. Hepatitis B-Related Hepatic Flare During Immune Reconstitution Syndrome After Antiretroviral Treatment Initiation in an HBV Surface Antigen-Positive Patient With HIV: Viroimmunological and Histological Characterization. Open Forum Infect Dis. 2022;9(9):ofac451.","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"3178_CR32","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1186\/s12879-024-09431-9","volume":"24","author":"W Fu","year":"2024","unstructured":"Fu W, Deng ZW, Wang P, Zhu ZW, Pu Y, Xie ZB, Li YZ, Yu HY. A complex case study: coexistence of multi-drug-resistant pulmonary tuberculosis, HBV-related liver failure, and disseminated cryptococcal infection in an AIDS patient. BMC Infect Dis. 2024;24(1):533.","journal-title":"BMC Infect Dis"},{"issue":"10","key":"3178_CR33","doi-asserted-by":"publisher","first-page":"e640","DOI":"10.1016\/S2352-3018(23)00151-0","volume":"10","author":"A Avihingsanon","year":"2023","unstructured":"Avihingsanon A, Lu H, Leong CL, Hung CC, Koenig E, Kiertiburanakul S, Lee MP, Supparatpinyo K, Zhang F, Rahman S, D\u2019antoni ML, Wang H, Hindman JT, Martin H, Baeten JM, Li T. Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 and hepatitis B coinfection (ALLIANCE): a double-blind, multicentre, randomised controlled, phase 3 non-inferiority trial. Lancet HIV. 2023;10(10):e640\u201352.","journal-title":"Lancet HIV"},{"issue":"4","key":"3178_CR34","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/S1473-3099(10)70026-8","volume":"10","author":"M M\u00fcller","year":"2010","unstructured":"M\u00fcller M, Wandel S, Colebunders R, Attia S, Furrer H, Egger M. Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis. Lancet Infect Dis. 2010;10(4):251\u201361.","journal-title":"Lancet Infect Dis"},{"issue":"8","key":"3178_CR35","doi-asserted-by":"publisher","first-page":"599","DOI":"10.7326\/L19-0477","volume":"171","author":"NC Bahr","year":"2019","unstructured":"Bahr NC, Yarlagadda SG. Fanconi Syndrome and Tenofovir Alafenamide. Ann Intern Med. 2019;171(8):599\u2013600.","journal-title":"Ann Intern Med"},{"issue":"9","key":"3178_CR36","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1097\/QAD.0000000000003916","volume":"38","author":"L Campbell","year":"2024","unstructured":"Campbell L, Barbini B, Cromarty B, Hamzah L, Williams D, Winston A, Post FA. Safety of tenofovir alafenamide in people with HIV who experienced proximal renal tubulopathy on tenofovir disoproxil. Aids. 2024;38(9):1442\u20135.","journal-title":"Aids"},{"issue":"13","key":"3178_CR37","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1097\/QAD.0000000000003987","volume":"38","author":"R Hurchund","year":"2024","unstructured":"Hurchund R, Sibiya SE, Owaga BO, Owira PMO. Tenofovir alafenamide compared to tenofovir disoproxil fumarate, induces dysglycemia, and dyslipidemia in Wistar rats. Aids. 2024;38(13):1809\u201318.","journal-title":"Aids"},{"issue":"8","key":"3178_CR38","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1001\/jamaoncol.2025.1589","volume":"11","author":"CB Haas","year":"2025","unstructured":"Haas CB, Mcgee-Avila JK, Luo Q, Pfeiffer RM, Gershman S, Cherala S, Cohen C, Monterosso A, Archer N, Insaf TZ, Engels EA, Shiels MS. Cancer Incidence and Trends in US Adults With HIV. JAMA Oncol. 2025;11(8):855\u201363.","journal-title":"JAMA Oncol"},{"issue":"1","key":"3178_CR39","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s40121-024-01083-1","volume":"14","author":"B Rossetti","year":"2025","unstructured":"Rossetti B, Ferrara M, Taramasso L, Bai F, Lombardi F, Ciccarelli N, Durante M, Alladio F, Bonazza F, Rancan I, Montagnani F, Di Biagio A, Monforte AD, Zazzi M, Fabbiani M. Evolution of Self-reported Neuropsychiatric Symptoms After Switching from Dolutegravir\/Abacavir\/Lamivudine to Bictegravir\/Emtricitabine\/Tenofovir Alafenamide: Results from the Randomized DOBINeuro Trial. Infect Dis Ther. 2025;14(1):293\u2013304.","journal-title":"Infect Dis Ther"},{"issue":"8","key":"3178_CR40","doi-asserted-by":"publisher","first-page":"e0289132","DOI":"10.1371\/journal.pone.0289132","volume":"18","author":"N Squillace","year":"2023","unstructured":"Squillace N, Ricci E, Maggi P, Taramasso L, Menzaghi B, De Socio GV, Piconi S, Maurizio Celesia B, Orofino G, Sarchi E, Pellican\u00f2 GF, Simeone F, Valsecchi L, Bandera A, Cenderello G, Attala L, Angioni G, Falasca K, Cascio A, Bargiacchi O, Di Biagio A, Bonfanti P. Real-life safety of Emtricitabine\/Tenofovir Alafenamide\/Bictegravir. PLoS ONE. 2023;18(8):e0289132.","journal-title":"PLoS ONE"},{"issue":"3","key":"3178_CR41","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s40261-023-01250-1","volume":"43","author":"JL Sanchez","year":"2023","unstructured":"Sanchez JL, Khiella M, Khoury M, Aryal BB, Verda L. A Fatal Case of Bictegravir-Induced Fulminant Hepatic Failure. Clin Drug Investig. 2023;43(3):205\u20138.","journal-title":"Clin Drug Investig"},{"key":"3178_CR42","doi-asserted-by":"publisher","first-page":"1564127","DOI":"10.3389\/fphar.2025.1564127","volume":"16","author":"H Xie","year":"2025","unstructured":"Xie H, Jiang L, Peng J, Hu H, Han M, Zhao B. Drug-induced pancreatitis: a real-world analysis of the FDA Adverse Event Reporting System and network pharmacology. Front Pharmacol. 2025;16:1564127.","journal-title":"Front Pharmacol"},{"issue":"10","key":"3178_CR43","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1177\/0956462420934981","volume":"31","author":"A Riva","year":"2020","unstructured":"Riva A, Cattaneo D, Filice C, Gervasoni C. Bictegravir\/emtricitabine\/tenofovir alafenamide-induced acute pancreatitis: a case report. Int J STD AIDS. 2020;31(10):1008\u201310.","journal-title":"Int J STD AIDS"},{"key":"3178_CR44","doi-asserted-by":"publisher","unstructured":"Simeni Njonnou SR, Henrard S, Noure L, Goffard JC. Severe rhabdomyolysis and acute asymptomatic pancreatitis following the concomitant use of Biktarvy in the setting of hyperosmolar diabetic crisis. BMJ Case Rep. 2020;13(7):e234483. Published 2020 Jul 1. https:\/\/doi.org\/10.1136\/bcr-2020-234483","DOI":"10.1136\/bcr-2020-234483"},{"issue":"4","key":"3178_CR45","doi-asserted-by":"publisher","first-page":"e0231883","DOI":"10.1371\/journal.pone.0231883","volume":"15","author":"D Wolfe","year":"2020","unstructured":"Wolfe D, Kanji S, Yazdi F, Barbeau P, Rice D, Beck A, Butler C, Esmaeilisaraji L, Skidmore B, Moher D, Hutton B. Drug induced pancreatitis: A systematic review of case reports to determine potential drug associations. PLoS ONE. 2020;15(4):e0231883.","journal-title":"PLoS ONE"},{"key":"3178_CR46","doi-asserted-by":"publisher","first-page":"120329","DOI":"10.1016\/j.lfs.2022.120329","volume":"294","author":"SC Maandi","year":"2022","unstructured":"Maandi SC, Maandi MT, Patel A, Manville RW, Mabley JG. Divergent effects of HIV reverse transcriptase inhibitors on pancreatic beta-cell function and survival: Potential role of oxidative stress and mitochondrial dysfunction. Life Sci. 2022;294:120329.","journal-title":"Life Sci"},{"issue":"1","key":"3178_CR47","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.pan.2024.12.005","volume":"25","author":"G Cai","year":"2025","unstructured":"Cai G, Szalai E, Martinekova P, Li X, Qian X, Veres DS, P\u00e9terfi Z, Biswakarma J, Nagy R, Mik\u00f3 A, \u00c1brah\u00e1m S, Er\u0151ss B, Hegyi P, Szentesi A. Concomitant virus infection increases mortality and worsens outcome of acute pancreatitis: A systematic review and meta-analysis. Pancreatology. 2025;25(1):20\u20138.","journal-title":"Pancreatology"},{"key":"3178_CR48","doi-asserted-by":"publisher","unstructured":"Rajalingamgari P, Khatua B, Summers MJ, et al. Prospective observational study and mechanistic evidence showing lipolysis of circulating triglycerides worsens hypertriglyceridemic acute pancreatitis. J Clin Invest. 2024;135(1):e184785. Published 2024 Nov 7. https:\/\/doi.org\/10.1172\/JCI184785","DOI":"10.1172\/JCI184785"},{"issue":"10","key":"3178_CR49","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1093\/clinchem\/hvad094","volume":"69","author":"SEJ Hansen","year":"2023","unstructured":"Hansen SEJ, Varbo A, Nordestgaard BG, Langsted A. Hypertriglyceridemia-Associated Pancreatitis: New Concepts and Potential Mechanisms. Clin Chem. 2023;69(10):1132\u201344.","journal-title":"Clin Chem"},{"issue":"11","key":"3178_CR50","doi-asserted-by":"publisher","first-page":"3824","DOI":"10.1128\/AAC.00437-06","volume":"50","author":"F Vidal","year":"2006","unstructured":"Vidal F, Domingo JC, Guallar J, Saumoy M, Cordobilla B, De La S\u00e1nchez R, Giralt M, Alvarez ML, L\u00f3pez-Dupla M, Torres F, Villarroya F, Cihlar T, Domingo P. In vitro cytotoxicity and mitochondrial toxicity of tenofovir alone and in combination with other antiretrovirals in human renal proximal tubule cells. Antimicrob Agents Chemother. 2006;50(11):3824\u201332.","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"3178_CR51","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/S2468-1253(19)30421-2","volume":"5","author":"P Lampertico","year":"2020","unstructured":"Lampertico P, Buti M, Fung S, Ahn SH, Chuang WL, Tak WY, Ramji A, Chen CY, Tam E, Bae H, Ma X, Flaherty JF, Gaggar A, Lau A, Liu Y, Wu G, Suri V, Tan SK, Subramanian GM, Trinh H, Yoon SK, Agarwal K, Lim YS, Chan HLY. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority study. Lancet Gastroenterol Hepatol. 2020;5(5):441\u201353.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"3178_CR52","doi-asserted-by":"publisher","first-page":"ofae746","DOI":"10.1093\/ofid\/ofae746","volume":"12","author":"N Akbar","year":"2025","unstructured":"Akbar N, Mariuz P. Disseminated TB With IRIS Presenting as a Pancreatic Mass in Newly Diagnosed HIV: A Case Report. Open Forum Infect Dis. 2025;12(1):ofae746.","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"3178_CR53","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/S0002-9343(99)00169-2","volume":"107","author":"T Dassopoulos","year":"1999","unstructured":"Dassopoulos T, Ehrenpreis ED. Acute pancreatitis in human immunodeficiency virus-infected patients: a review. Am J Med. 1999;107(1):78\u201384.","journal-title":"Am J Med"},{"issue":"5","key":"3178_CR54","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1093\/cid\/ciae218","volume":"79","author":"LM Holt","year":"2024","unstructured":"Holt LM, Short WR, Momplaisir F, Hyun E, Mckinney J, Lugo Morales A, Duque A, Druyan B, Ndubizu C, Duthely L, Joseph N, Sheth AN, Badell ML. Bictegravir Use During Pregnancy: A Multicenter Retrospective Analysis Evaluating HIV Viral Suppression and Perinatal Outcomes. Clin Infect Dis. 2024;79(5):1258\u201361.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"3178_CR55","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1093\/cid\/ciae474","volume":"80","author":"CD Lahiri","year":"2025","unstructured":"Lahiri CD, Mehta CC, Yang Q, Maramba T, Musonge-Effoe J, Yang CA, Dumond JB, Alcaide ML, Lake JE, Rubin LH, French AL, Cocohoba J, Kassaye SG, Sharma A, Palella FJ, Mellors J, Konkle-Parker D, Topper E, Augenbraun M, Ali MK, Sheth AN, Ziegler TR, Ofotokun I, Alvarez JA. Short and Long-term Body Weight Change Following the Switch to or the Addition of Integrase Inhibitors in Persons With HIV Differs by Sex. Clin Infect Dis. 2025;80(3):575\u201384.","journal-title":"Clin Infect Dis"},{"issue":"42","key":"3178_CR56","doi-asserted-by":"publisher","first-page":"e31349","DOI":"10.1097\/MD.0000000000031349","volume":"101","author":"K Konishi","year":"2022","unstructured":"Konishi K, Nakagawa H, Asaoka T, Kasamatsu Y, Goto T, Shirano M. Sarcopenia among people living with HIV and the effect of antiretroviral therapy on body composition. Med (Baltim). 2022;101(42):e31349.","journal-title":"Med (Baltim)"},{"issue":"1","key":"3178_CR57","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.2105\/AJPH.2018.304727","volume":"109","author":"JS Becasen","year":"2019","unstructured":"Becasen JS, Denard CL, Mullins MM, Higa DH, Sipe TA. Estimating the Prevalence of HIV and Sexual Behaviors Among the US Transgender Population: A Systematic Review and Meta-Analysis, 2006\u20132017. Am J Public Health. 2019;109(1):e1\u20138.","journal-title":"Am J Public Health"},{"issue":"11","key":"3178_CR58","doi-asserted-by":"publisher","first-page":"2653","DOI":"10.1093\/jac\/dkad270","volume":"78","author":"M Loutfy","year":"2023","unstructured":"Loutfy M, Lacombe-Duncan A, Tseng A, Persad Y, Underhill A, Kennedy VL, Armstrong I, Fung R, Bourns A, Nguyen Q, Hranilovic S, Weisdorf T, Chan LYL, Kia H, Halpenny R, Iyer H, Jeyarajah N, Kovchazov G, Mccully J, Scarsi KK. Oestradiol concentrations in trans women with HIV suppressed on unboosted integrase inhibitor regimens versus trans women without HIV taking oral oestradiol: a pilot study. J Antimicrob Chemother. 2023;78(11):2653\u20139.","journal-title":"J Antimicrob Chemother"},{"key":"3178_CR59","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.phrs.2016.04.028","volume":"110","author":"DA Dalwadi","year":"2016","unstructured":"Dalwadi DA, Kim S, Amdani SM, Chen Z, Huang RQ, Schetz JA. Molecular mechanisms of serotonergic action of the HIV-1 antiretroviral efavirenz. Pharmacol Res. 2016;110:10\u201324.","journal-title":"Pharmacol Res"},{"issue":"6","key":"3178_CR60","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1007\/s13365-017-0573-5","volume":"23","author":"KL Stauch","year":"2017","unstructured":"Stauch KL, Emanuel K, Lamberty BG, Morsey B, Fox HS. Central nervous system-penetrating antiretrovirals impair energetic reserve in striatal nerve terminals. J Neurovirol. 2017;23(6):795\u2013807.","journal-title":"J Neurovirol"},{"issue":"5","key":"3178_CR61","doi-asserted-by":"publisher","first-page":"ofab077","DOI":"10.1093\/ofid\/ofab077","volume":"8","author":"NS Nolan","year":"2021","unstructured":"Nolan NS, Adamson S, Reeds D, O\u2019halloran JA. Bictegravir-Based Antiretroviral Therapy-Associated Accelerated Hyperglycemia and Diabetes Mellitus. Open Forum Infect Dis. 2021;8(5):ofab077.","journal-title":"Open Forum Infect Dis"},{"issue":"null","key":"3178_CR62","first-page":"1","volume":"19","author":"R Zheng","year":"2026","unstructured":"Zheng R, Zhang Z, Yan J, Li F, Shi J. Acute Pancreatitis Secondary to Hyperlipidemia After Exposure to Biktarvy and Alcohol in a HIV-Positive Patient:A Case Report. Int Med Case Rep J. 2026;19(null):1\u20137.","journal-title":"Int Med Case Rep J"},{"key":"3178_CR63","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.2147\/JIR.S485804","volume":"18","author":"M Luo","year":"2025","unstructured":"Luo M, Jin T, Fang Y, Chen F, Zhu L, Bai J, Ding J. Signaling Pathways Involved in Acute Pancreatitis. J Inflamm Res. 2025;18:2287\u2013303.","journal-title":"J Inflamm Res"},{"key":"3178_CR64","doi-asserted-by":"publisher","first-page":"115109","DOI":"10.1016\/j.intimp.2025.115109","volume":"162","author":"H Zhang","year":"2025","unstructured":"Zhang H, Wang Z, Li J, Jia Y, Xie X, Ding Y, Cao F, Li F. Inhibition of MMP9 ameliorates neutrophil extracellular traps-mediated necroptosis through regulation of impaired autophagy in severe acute pancreatitis. Int Immunopharmacol. 2025;162:115109.","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"3178_CR65","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s40520-024-02921-5","volume":"37","author":"L Liu","year":"2025","unstructured":"Liu L, Wu S, Wei L, Xia Z, Ji J, Huang D. Romosozumab adverse event profile: a pharmacovigilance analysis based on the FDA Adverse Event Reporting System (FAERS) from 2019 to 2023. Aging Clin Exp Res. 2025b;37(1):23.","journal-title":"Aging Clin Exp Res"},{"key":"3178_CR66","doi-asserted-by":"publisher","first-page":"789","DOI":"10.2147\/CLEP.S365513","volume":"14","author":"Y Shu","year":"2022","unstructured":"Shu Y, He X, Liu Y, Wu P, Zhang Q. A Real-World Disproportionality Analysis of Olaparib: Data Mining of the Public Version of FDA Adverse Event Reporting System. Clin Epidemiol. 2022a;14:789\u2013802.","journal-title":"Clin Epidemiol"},{"issue":"1","key":"3178_CR67","doi-asserted-by":"publisher","first-page":"e70084","DOI":"10.1002\/pds.70084","volume":"34","author":"L Hai","year":"2025","unstructured":"Hai L, Wu J, Pan X, Yin W, Wu Z. A Real-World Pharmacovigilance Study of FDA Adverse Event Reporting System Events for Obeticholic Acid. Pharmacoepidemiol Drug Saf. 2025;34(1):e70084.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"3178_CR68","doi-asserted-by":"crossref","unstructured":"Liu JF, Bai YT, Leng YE, Chang E, Wei YX, Wei W. (2025a). Post-marketing safety concerns with luspatercept: a disproportionality analysis of the FDA adverse event reporting system. Expert Opin Drug Saf: 1\u20138.","DOI":"10.1080\/14740338.2025.2464071"}],"container-title":["Virology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12985-026-03178-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-026-03178-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-026-03178-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T04:09:31Z","timestamp":1785816571000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12985-026-03178-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,30]]},"references-count":68,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3178"],"URL":"https:\/\/doi.org\/10.1186\/s12985-026-03178-2","relation":{},"ISSN":["1743-422X"],"issn-type":[{"value":"1743-422X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,30]]},"assertion":[{"value":"24 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethical approval was not required as the study was conducted using de-identified publicly available data. the consent procedure was not required.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"184"}}